Oral compositions containing a salivation inducing agent
View Patent ↗Oral dosage forms, and particles used therein, containing salivation inducing agents are disclosed. The salivation agents may be in the core of the dosage form and/or in coatings applied thereto, or alternatively may be within particles and/or the matrix of such dosage forms, in coatings applied to such particles, or on the surface of such coated particles. The particles may be produced into a tablet form, such as a chewable tablet form, that provides for the immediate release of the active ingredient. Other oral dosage forms include thin film strips, gummi, foam tabs, and lozenges.
1. A method of administering a pharmaceutically active ingredient, said method comprising placing in the oral cavity a tablet comprising particles, wherein said particles comprise, based upon the total dry weight of the particle,:
a) a core containing an active ingredient; and
b) a taste-masking coating layer substantially covering the core, and
c) from about 0.1% to about 25% of a salivation inducing agent layer substantially covering the taste-masking coating layer;
wherein said particle has a size of from about 50 microns to about 1000 microns and wherein said method comprises chewing said tablet and/or allowing said tablet to disintegrate in the oral cavity prior to swallowing said tablet.
2. The method of claim 1 , wherein the salivation inducing agent is selected from the group consisting of tasteless muscarinic acetylcholine receptor agonists; N, N-disubstituted phenylalkylamines wherein the alkyl has from about 1 to about 8 carbons; spirooxathiolane-quinuclidine; Heliopsis longpipes root; cholinesterase inhibitors; and mixtures thereof.
3. The method of claim 1 , wherein the salivation inducing agent is selected from the group consisting of pilocarpine; N, N-disubstituted-2-phenylcyclopropylamines; spirooxathiolane-quinuclidine; Heliopsis longpipes root;
cholinesterase inhibitors; and mixtures thereof.
4. The method of claim 1 wherein the salivation inducing agent has a salivation-inducing value of at least about 12%.
5. The method of claim 3 wherein the salivation inducing agent has a salivation-inducing value of at least about 12%.
6. The method of claim 1 , wherein the active ingredient is a nonsteroidal anti-inflammatory drug, acetaminophen, pseudoephedrine, phenylpropanolamine, chlorpheniramine, dextromethorphan, diphenhydramine, dimenhydrinate, meclizine, famotidine, loperamide, ranitidine, cimetidine, astemizole, loratadine, desloratadine, fexofenadine, cetirizine, antacids, oxybutynin, methylphenidate, pharmaceutically acceptable salts thereof, and mixtures thereof.
7. The method of claim 5 , wherein the active ingredient is a nonsteroidal anti-inflammatory drug, acetaminophen, pseudoephedrine, phenylpropanolamine, chlorpheniramine, dextromethorphan, diphenhydramine, dimenhydrinate, meclizine, famotidine, loperamide, ranitidine, cimetidine, astemizole, loratadine, desloratadine, fexofenadine, cetirizine, antacids, oxybutynin, methylphenidate, pharmaceutically acceptable salts thereof, and mixtures thereof.
8. The method of claim 1 wherein the tablet meets the USP dissolution specification for the 2000 Version of the USP for immediate release tablets containing the particular active ingredient.
9. The method of claim 7 wherein the tablet meets the USP dissolution specification for the 2000 Version of the USP for immediate release tablets containing the particular active ingredient.
10. A method of administering a pharmaceutically active ingredient, said method comprising placing in the oral cavity a tablet comprising particles, wherein said particles comprise, based upon the total dry weight of the particle,:
a) a core containing an active ingredient; and
b) a coating substantially covering the core, said coating comprised of from about 0.1% to about 25% of a salivation inducing agent;
wherein said particle has a size of from about 50 microns to about 1000 microns and wherein said method comprises chewing said tablet and/or allowing said tablet to disintegrate in the oral cavity prior to swallowing said tablet.
11. The method of claim 10 , wherein the salivation inducing agent is selected from the group consisting of tasteless muscarinic acetylcholine receptor agonists; N, N-disubstituted phenylalkylamines wherein the alkyl has from about 1 to about 8 carbons; spirooxathiolane-quinuclidine; Heliopsis longpipes root; cholinesterase inhibitors; and mixtures thereof.
12. The method of claim 10 , wherein the salivation inducing agent is selected from the group consisting of pilocarpine; N, N-disubstituted-2- phenylcyclopropylamines; spirooxathiolane-quinuclidine; Heliopsis longpipes root;
cholinesterase inhibitors; and mixtures thereof.
13. The method of claim 10 wherein the salivation inducing agent has a salivation-inducing value of at least about 12%.
14. The method of claim 12 wherein the salivation inducing agent has a salivation-inducing value of at least about 12%.
15. The method of claim 10 , wherein the active ingredient is a nonsteroidal anti-inflammatory drug, acetaminophen, pseudoephedrine, phenylpropanolamine, chlorpheniramine, dextromethorphan, diphenhydramine, dimenhydrinate, meclizine, famotidine, loperamide, ranitidine, cimetidine, astemizole, loratadine, desloratadine, fexofenadine, cetirizine, antacids, oxybutynin, methylphenidate, pharmaceutically acceptable salts thereof, and mixtures thereof.
16. The method of claim 14 , wherein the active ingredient is a nonsteroidal anti-inflammatory drug, acetaminophen, pseudoephedrine, phenylpropanolamine, chlorpheniramine, dextromethorphan, diphenhydramine, dimenhydrinate, meclizine, famotidine, loperamide, ranitidine, cimetidine, astemizole, loratadine, desloratadine, fexofenadine, cetirizine, antacids, oxybutynin, methylphenidate, pharmaceutically acceptable salts thereof, and mixtures thereof.
17. The method of claim 10 wherein the tablet meets the USP dissolution specification for the 2000 Version of the USP for immediate release tablets containing the particular active ingredient.
18. The method of claim 16 wherein the tablet meets the USP dissolution specification for the 2000 Version of the USP for immediate release tablets containing the particular active ingredient.